Program
HRS-4357
A development code. Also written as “HRS-4357 injection”.
In Jiangsu HengRui Medicine's pipeline, PSMA
. Its studies are mostly in Prostatic Neoplasms, led by Jiangsu HengRui Medicine.
Furthest: phase 3, since Dec 16, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 22 open or running | phase 3since Dec 16, 2025 | Aug 8, 2023 | Dec 2027phase 3 · NCT07311694 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-4357
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 8, 2023First study: phase 2 study in Advanced Prostate CancerFirst studyNCT06006104 · 49 planned
- Dec 16, 2025Phase 3 study in PSMA-Positive Progressive Metastatic Castration-Resistant Prostate CancerPhase 3 reachedNCT07311694 · 370 planned · China
Ahead
- Dec 2027Primary completion: phase 3 study in PSMA-Positive Progressive Metastatic Castration-Resistant Prostate CancerNCT07311694
TargetBeta
“PSMA”the company's pipeline, read by Claude · source
Other programs on FOLH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| flotufolastat F 18rule | Bracco | phase 4 | 7 |
| piflufolastatrule | Lantheus | phase 4 | 5 |
| abefolastat tesaroxetan CU-64rule | clarity-pharmaceuticals-ltd | phase 3 | 5 |
| gallium 68 PSMA-11rule | Novartis | phase 3 | 4 |
| Lutetium Lu 177 Ludotadipeprule | futurechem | phase 3 | 3 |
| Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 | Johnson & Johnson | phase 3 | 2 |
| Lutetium Lu 177 NYM032rule | Norroy Bioscience | phase 3 | 2 |
| actinium AC-225 vipivotide tetraxetan | Novartis | phase 3 | 2 |
| zadavotide guraxetan | AstraZeneca | phase 2 | 4 |
| AB-001rule | frontier-biotechnologies-inc | phase 2 | 3 |
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 2 |
| SHR-4394 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07311694PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer · China | 3 | Recruiting | Dec 2027 | 370 |
| NCT06006104Advanced Prostate Cancer | 2 | Not yet recruiting | Sep 30, 2024 | 49 |
How it is read
Names in the registry
- “HRS-4357 injection”, 2 entries
Codes read as this program: HRS4357.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.